SMAD5 and neoplasm: Conversely, pharmacologic targeting of Aurora-A restores chemosensitivity through inhibition of SMAD5 transcriptional activity leading to restoration of a more differentiated luminal CD44-/CD24+/PROCR- phenotype with low ALDH1 activity and impairment of tumor stemness.